At Novelion Therapeutics, and our subsidiary Aegerion Pharmaceuticals, we seek to develop new standards of care for individuals living with rare diseases. We depend on the commitment, ideas and actions of each individual employee to advance patient care and a create sustainable future for our organization.
Our Pipeline: Status of Selected Key Development Programs as of November 2016; represents ongoing phase of development; does not correspond to initiation or completion of a particular phase.
- Phase 1
- Phase 2
- Phase 3
* Click here for JUXTAPID® (lomitapide) full US prescribing information, including BOXED WARNING for the risk of hepatotoxicity.
** Click here for MYALEPT® (metreleptin) full US prescribing information, including BOXED WARNING for the risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma.
*** Plan to submit MAA for metreleptin in EU to treat GL and a subset of PL